Oxygen Of The Saccharide Radical Bonded Directly To A Nonsaccharide Hetero Ring Or A Polycyclo Ring System Which Contains A Nonsaccharide Hetero Ring Patents (Class 514/27)
  • Patent number: 11172695
    Abstract: A method and composition for providing hydrolyzed starch and fiber. In one aspect, the method comprises providing a first enzyme; a second enzyme; water; and a starting composition comprising at least one material selected from the group consisting of at least a portion of grain and at least a portion of pulse. Additional steps comprise hydrolyzing the fiber and starch in the at least one material through fiber and starch hydrolysis reactions catalyzed by the first and second enzymes, respectively. Further steps comprise deactivating the first and second enzymes. In a second aspect, a composition comprises at least one material selected from the group consisting of at least a portion of grain and at least a portion of pulse. The average molecular weights of the hydrolyzed starch and fiber molecules in the composition are fractions of the molecular weights of unhydrolyzed starch and fiber molecules, respectively.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: November 16, 2021
    Assignee: The Quaker Oats Company
    Inventors: Khushal Brijwani, Gary Carder, Yongsoo Chung, Ursula Vanesa Lay Ma, John Schuette, Wesley Twombly
  • Patent number: 11164675
    Abstract: It is provided a treatment selection support system comprising: a target achievement determination module configured to create target achievement determination information; a blood sugar controllability estimation module configured to create blood sugar controllability information; an achievement level prediction model creation module configured to create an achievement level prediction model; an appropriateness level calculation model creation module configured to create an appropriateness level calculation model for calculating an appropriateness level of a blood sugar control means based on formatted information, the target achievement determination information, and the blood sugar controllability information; an achievement level prediction module configured to use the achievement level prediction model; an appropriateness level calculation module configured to use the appropriateness level calculation model; and a blood sugar control means suggestion module configured to provide information on the blood
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: November 2, 2021
    Assignee: HITACHI, LTD.
    Inventors: Shinji Tarumi, Wataru Takeuchi
  • Patent number: 11154546
    Abstract: The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to ameliorate mitochondrial toxicity caused by administration of a chemical, food, or drug.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: October 26, 2021
    Assignee: Epirium Bio Inc.
    Inventors: Francisco Villarreal, Alan Maisel, George Schreiner, Guillermo M. Ceballos Reyes, Pam Taub
  • Patent number: 11147792
    Abstract: The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: October 19, 2021
    Assignees: AXIAL THERAPEUTICS, INC., CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Timothy Sampson, Sarkis Mazmanian, Anthony Stewart Campbell
  • Patent number: 11122997
    Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 21, 2021
    Assignees: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke University
    Inventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
  • Patent number: 11116708
    Abstract: Personal care compositions including a naringin:zinc complex and methods for preparing and using the same are provided. The personal care compositions may include a carrier and a naringin:zinc complex having a 2:1 naringin to zinc molar ratio.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 14, 2021
    Assignee: Colgate-Palmolive Company
    Inventors: Shujiang Cheng, Zeenat Nabi, Laurence Du-Thumm, Qiang Wu, Jane Ong, Halyna Siomyk, Harsh Mahendra Trivedi, James Masters, Chi-Yuan Cheng, Donghui Wu
  • Patent number: 11117919
    Abstract: An icariside compound as shown in Formula I wherein the compound is a natural chemical component in the traditional Chinese herbal epimedium or a chemically modified or a totally synthetic product based on the natural component. The compound can be used for preparing pharmaceuticals, health care products, cosmetic and skin care products and the like for improvement of immunity in a human body.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: September 14, 2021
    Assignee: GOLDEN HEALTH (GUANGDONG) BIOTECHNOLOGY CO. LTD.
    Inventors: Lianquan Gu, Changyou Wu, Jinlin Zhou, Yujing Lu, Tianmiao Ou, Baohua Huang, Liwei Lin
  • Patent number: 11084843
    Abstract: The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: August 10, 2021
    Assignee: GODAVARI BIOREFINERIES LTD.
    Inventors: Vitthal Yadav, Maithili Athavale, Prashant Kharkar, Sangeeta Srivastava, Samir Somaiya, Smera Satish, Sandip Gavade
  • Patent number: 11058654
    Abstract: This disclosure provides compositions and methods for improving erythrocyte dysfunction or treating a hemoglobinopathy or a thalassemia (e.g., sickle cell disease or ?-thalassemia).
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: July 13, 2021
    Assignee: AXCELLA HEALTH INC.
    Inventors: Sean Carroll, Matthew Russell, Raffi Afeyan
  • Patent number: 11045513
    Abstract: Association comprising: —dry extract of: a) Vicia faba, b) Uncaria rhyncophylla and c) liquorice root, —coenzyme Q10, and preferably at least one vitamin chosen from vitamin C and E for use as coadjuvant for improving the quality of life (QOL) in subjects with movement disorders and in particular in subjects suffering from Parkinson's disease. This association is preferably in an oral formulation, more preferably in the form of a food supplement.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: June 29, 2021
    Assignee: CRISTALFARMA S.R.L.
    Inventors: Maria Cristina Del Bono, Francesco Bonomo
  • Patent number: 11033528
    Abstract: A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a helicase ATPase inhibitor, a sialidase enzyme inhibitor, and ICAM-1 inhibitor which each also down regulate the immune response. The composition may further include a permeation enhancer.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: June 15, 2021
    Assignee: GLOBAL BIOLIFE INC.
    Inventor: Daryl Thompson
  • Patent number: 11034959
    Abstract: The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: June 15, 2021
    Assignee: Institute For Cancer Research
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • Patent number: 11020415
    Abstract: Use of albiflorin or a pharmaceutically acceptable salt thereof in the preparation of a product for regulating and improving the balance of human intestinal flora. Albiflorin or a pharmaceutically acceptable salt thereof, as a regulator for improving the function of intestinal flora system, can be used in the preparation of a medicament, a health care product, a food, a food additive, or a nutritional supplement that ameliorates and treats a sub-health status and/or a disease caused by intestinal flora disturbance; the sub-health status is selected from intestinal system dysfunction and/or affective disorder; and the disease is selected from one or more of irritable bowel syndrome, depression, anxiety, colitis, and colon cancer.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: June 1, 2021
    Inventor: Zuoguang Zhang
  • Patent number: 11013777
    Abstract: This invention relates to the use of an Aronia berry extract or a composition comprising said extract for enhancing the reaction time, attention, concentration and psychomotor control of a mammal, more in particular a human. The composition comprising the Aronia extract is formulated for oral ingestion.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: May 25, 2021
    Assignee: BioActor BV
    Inventors: Antonie Johannes Van der Saag, Mandy Lambrix, Yala Stevens
  • Patent number: 10980775
    Abstract: The present invention relates to a pharmaceutical composition or medical device comprising a fucoidan and at least one compound of formula A or B: wherein R1 and R2 are independently selected from the group consisting of —OH, —CH3, —CF3CH2O—, and CH3O—. Such pharmaceutical composition or medical device is notably useful for the treatment and/or prevention of a skin disorder involving excessive angiogenesis and/or fibrogenesis, such as in skin fibrosis, angiofibromas, hamartomas and periungual fibromas, skin manifestation occurring with rosacea, acne, atopic dermatitis, scleroderma, psoriasis and lupus erythematosus, and especially of Tuberous Sclerosis Complex and skin manifestation occurring with Tuberous Sclerosis Complex.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: April 20, 2021
    Assignee: Xantial
    Inventor: Gilles Henri Lasserre
  • Patent number: 10959980
    Abstract: The present invention discloses a composition comprising not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use in the therapeutic management of hypertriglyceridemia, associated with chemotherapy and hyperglycemia.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: March 30, 2021
    Assignee: SAMI-SABINSA GROUP LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • Patent number: 10894029
    Abstract: Disclosed are compositions containing not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use in the therapeutic management of memory impairment and cognitive dysfunction. More specifically, the invention discloses the use of abovementioned compositions for the management of cognitive impairment induced by chemotherapy and hyperglycemia.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: January 19, 2021
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • Patent number: 10881623
    Abstract: Disclosed is a method for therapeutic management of hyperglycemia in mammals using compositions containing thymohydroquinone. More specifically, the invention discloses compositions containing thymohydroquinone for inhibiting the activity of the enzyme ?-glucosidase and increasing the cellular uptake of glucose by mammalian cells. The anti-oxidant, anti-inflammatory and anti-glycation effects of thymohydroquinone are also disclosed herein.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: January 5, 2021
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
  • Patent number: 10842169
    Abstract: A food composition for managing non-food allergies in companion animals is disclosed, along with a method of managing non-food allergies.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 24, 2020
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Kathy Gross, Jennifer Macleay, Dale Allen Fritsch, Geoff Bednar, Kiran Panickar, Inke Paetau-Robinson, Dennis Jewell
  • Patent number: 10828324
    Abstract: Methods are provided to make clinoptilolite into a water-soluble hydrolyzed form suitable for various administration routes, including oral administration. Absorption of water-soluble hydrolyzed clinoptilolite fragments can aid in detoxification by binding heavy metals and environmental toxins, can reduce reactive oxygen species and inflammation related to heavy metals and other/environmental toxins, resulting in an increase in energy, and/or in an increase in one or more of focus, concentration, and memory. Water-soluble hydrolyzed clinoptilolite fragments can be combined with one or more dietary supplements, including various vitamins and sleep aids.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: November 10, 2020
    Inventor: Nikolaos Tsirikos-Karapanos
  • Patent number: 10813868
    Abstract: The invention provides a method for improving the volume of hair which comprises the following steps: (i) treating the hair by topical application of a composition comprising from 1 to 25 wt % of one or more glucosamine salts; (ii) shaping the treated hair; (iii) allowing the composition to remain in contact with the shaped hair before drying. Advantageously the method of the invention does not require the breakage of the hair disulfide bonds, does not require the use of high temperature heated implements such as straightening irons, and can be accomplished by a consumer without intervention of a professional hairdresser.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: October 27, 2020
    Assignee: Conopco, Inc.
    Inventors: Ezat Khoshdel, Prem Kumar Cheyalazhagan Paul
  • Patent number: 10806744
    Abstract: Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. According to Node et al. (Cardiovascular diabetology, 8, 23 (2009)), repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: October 20, 2020
    Assignee: Conopco, Inc.
    Inventors: Mark Ian Fowler, Huijun Wang
  • Patent number: 10744113
    Abstract: A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: August 18, 2020
    Assignee: OSTEONEUROGEN INC.
    Inventors: Byung Soo Youn, Han Soo Kim, Ho Sup Yoon
  • Patent number: 10646489
    Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions comprise a combination of a PDE 5 inhibitor, such as sildenafil or icariin, and resveratrol, and a branched amino acid such as leucine, or its metabolite.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: May 12, 2020
    Assignee: NuSirt Sciences, Inc.
    Inventors: Michael Zemel, Antje Bruckbauer, Brooke Baggett
  • Patent number: 10639403
    Abstract: The present disclosure relates to a coated implantable medical device, comprising: a base layer comprising mTOR inhibitor, and at least one biodegradable polymer; a middle layer comprising mTOR inhibitor, and at least one biodegradable polymer; and a top layer selected from the group consisting of hydrophilic polymer, and combination of hydrophilic polymer and antioxidant, wherein the total mTOR inhibitor concentration over the medical device is in the range of 0.7 to 3.00 ?g/mm2. The present disclosure further relates to a method of preparing a coated implantable medical device.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: May 5, 2020
    Assignee: SAHAJANAND MEDICAL TECHNOLOGIES PRIVATE LIMITED
    Inventors: Ankur Jaykumar Raval, Chhaya Babubhai Engineer, Vandana Bharat Patravale
  • Patent number: 10639381
    Abstract: Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group -L1-(A-L2)a-B attached thereto, wherein a is an integer between 1 and 10, inclusive, L1 is absent or is a linking group, A is a moiety formed from the reaction of two complimentary groups (X and Y), L2 is absent or is another linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing these antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin-antibody drug conjugates, novel trioxacarcins without an antibody conjugated thereto, pharmaceutical compositions thereof, and methods of their use and treatment.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: May 5, 2020
    Inventors: Andrew G. Myers, Daniel J. Smaltz, Andreas Schumacher
  • Patent number: 10583145
    Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: March 10, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna
  • Patent number: 10576057
    Abstract: The present invention relates to a composition for preventing and treating muscle diseases or improving muscular function, containing, as an active ingredient, at least one selected from the group consisting of morusin, kuwanon G, and a Mori Cortex Radicis extract. The Mori Cortex Radicis extract, morusin, or kuwanon G, according to the present invention, has an effect of remarkably enhancing muscular function by increasing the expression of p-mTOR protein involved in muscular protein synthesis, inhibiting the expression of mRNAs of MuRF-1 and atrogin-1 involved in muscular protein degradation, and increasing the expression of mRNAs of MyoD and myogenin involved in muscular differentiation. In addition, the present invention is a natural product so as to be used safely without side effects, thereby being usable in drugs, food, or cosmetics.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: March 3, 2020
    Assignee: NEWTREE CO., LTD.
    Inventors: Jae-Kwan Hwang, Mi-Bo Kim, Changhee Kim, Doun Kim, Heechul Chung
  • Patent number: 10555982
    Abstract: Disclosed are the compositions comprising bioactive components Oroxylin A, Baicalein, Chrysin, and their glucuronides Oroxylin A-7-glucuronide, Baicalein-7-glucuronide and Chrysin-7-glucuronide, isolated from the bark of Oroxylum indicum, and the process of isolating the said bioactives.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: February 11, 2020
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Beena Bhat, Anurag Pande
  • Patent number: 10537601
    Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 21, 2020
    Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Jing-Rong Wang, Zhi-Hong Jiang, Qi-Tong Feng, Guo-Yuan Zhu, Wei-Na Gao, Zifeng Yang, Nanshan Zhong
  • Patent number: 10493021
    Abstract: The present invention provides stable antioxidant cosmetic formulations for topical use comprising green tea extract in combination with additional active compounds having the surprising ability to exert antioxidant effect on the skin, the use stable antioxidant cosmetic formulations, as well as a method for reducing and/or preventing oxidative stress in keratinous tissues.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: December 3, 2019
    Assignee: NATURA COSMÉTICOS S.A.
    Inventors: Ana Paula Pedroso De Oliveira, Cristiane Calvo De Santi, Gabriela Placoná Diniz, Jenny Chu Yan Ling Okuda, Juliana Carvalhães Lago, Kelen Fabíola Arroteia
  • Patent number: 10420756
    Abstract: The present invention relates to a method of reducing or preventing the symptoms associated with the intake of alcohol. The method comprises administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a H1-antihistamine.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 24, 2019
    Assignee: SEN-JAM PHARMACEUTICAL LLC.
    Inventors: Jacqueline M. Iversen, James M. Iversen
  • Patent number: 10383842
    Abstract: A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a helicase ATPase inhibitor, a sialidase enzyme inhibitor, and ICAM-1 inhibitor which each also down regulate the immune response. The composition may further include a permeation enhancer.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: August 20, 2019
    Assignee: GLOBAL BIOLIFE INC.
    Inventor: Daryl Thompson
  • Patent number: 10376465
    Abstract: The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: August 13, 2019
    Assignee: Pulmatrix Operating Company, Inc.
    Inventors: Michael M. Lipp, Jean C. Sung
  • Patent number: 10350230
    Abstract: Disclosed is a use of albiflorin or a pharmaceutically acceptable salt for the prevention and/or treatment of irritable bowel syndrome. The experimental results demonstrate that the prevention, remission and/or treatment of irritable bowel syndrome with albiflorin or a pharmaceutically acceptable salt has significant effects and few side effects. This is a preparation derived from a natural plant for the safe, effective and multi-targeted prevention, remission and/or treatment of irritable bowel syndrome.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: July 16, 2019
    Inventor: Zuoguang Zhang
  • Patent number: 10335356
    Abstract: The present invention discloses a use of neohesperidin or a neohesperidin-containing plant extract in the manufacture of a product for improving and/or promoting skin microcirculation, or for eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation. The present invention also discloses a composition comprising an effective amount of neohesperidin or a neohesperidin-containing plant extract, and to a method for improving and/or promoting skin microcirculation, or eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation, by using neohesperidin. The skin microcirculation of the present invention is preferably eye skin microcirculation.
    Type: Grant
    Filed: November 25, 2011
    Date of Patent: July 2, 2019
    Assignee: Natural Medicine Institute of Zhejiang Yangshengtang Co., Ltd.
    Inventors: Liu Hu, Hongying Lan
  • Patent number: 10328183
    Abstract: Various aspects of the present invention provide compositions and implantable devices including a water-insoluble therapeutic agent solubilized in a matrix of a gallate-containing compound. Other aspects provide methods of manufacturing and using such compositions and devices.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: June 25, 2019
    Assignee: COOK MEDICAL TECHNOLOGIES LLC
    Inventors: John Jackson, Lindsay Stuart Machan, Kevin Letchford
  • Patent number: 10285976
    Abstract: Compositions for treating autoimmune, allergic, or atopic disease comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, the compound that inhibits hyaluronan synthesis is 4-methylumbelliferone or a metabolite of 4-methylumbelliferone. Methods for treating autoimmune diabetes, multiple sclerosis and/or autoimmune demyelination, including administering to the subject a composition having a compound in an amount effective to inhibit hyaluronan synthesis in a mammalian subject, are also described.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: May 14, 2019
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON
    Inventors: Paul L. Bollyky, Nadine Nagy, Thomas Wight, Hedwich F. Kuipers
  • Patent number: 10286068
    Abstract: A vaccine composition is disclosed that contains a vaccine antigen and a neutrophil inhibitor in amounts effective to promote an IgA response to the antigen in a subject. Also disclosed is a method for enhancing immune response to a vaccine antigen in a subject that involves co-administering to the subject the vaccine antigen and an adjuvant composition comprising a neutrophil inhibitor in an amount effective to promote an IgA response to the vaccine antigen in the subject.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 14, 2019
    Assignee: Ohio State Innovation Foundation
    Inventor: Prosper Boyaka
  • Patent number: 10278949
    Abstract: A biotechnology process that employs membrane technology for obtaining an extract rich in tannins of ellagic acid from blackberries (Rubus spp.) and from other fruits that contain these compounds, as well as to the extract obtained using this method. The method is essentially based on baromembrane technologies that allow mechanical separation and effective fractionation between the polyphenol compounds, by interactions between the physico-chemical properties thereof, the material of the membrane and the molar mass of same, thereby allowing enrichment of a fraction of the natural extract with ellagic acid tannins and modification of the content thereof in terms of anthocyanins and other compounds such as sugars and acids.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: May 7, 2019
    Assignees: UNIVERSIDAD DE COSTA RICA, CENTRO INTERNACIONAL DE COOPERACION EN INVESTIGACION AGRICOLA PARA EL DESARROLLO, CIRAD, CENTRO INTERNACIONAL DE ESTUDIOS SUPERIORES EN CIENCIAS AGRONOMICAS, SUPAGRO
    Inventors: Oscar Gerardo Acosta Montoya, Ana Mercedes Perez Carvajal, Manuel Dornier, Fabrice Vaillant
  • Patent number: 10272099
    Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: April 30, 2019
    Assignees: The Board of Regents of the University of Texas System, The Board of Trustees of the University of Illinois.
    Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Lifen Cao, Jinming Gao, Xiumei Huang, Xiuquan Luo, Xinpeng Ma, Zachary R. Moore, Elizabeth I. Parkinson
  • Patent number: 10196417
    Abstract: A baicalin magnesium compound and methods for preparing and extracting the same. The method for preparing the baicalin magnesium compound includes steps of preparation of a baicalin suspension, preparation of a magnesium ion-containing suspension, reaction and drying. The method for extracting the baicalin magnesium compound includes steps of pretreatment of macroporous resin, extraction, adsorption and elution, concentration and drying and purification. The methods restores the baicalin to the original form as found in radix scutellariae, and the baicalin magnesium compound may be used as a substitute for the baicalin in pharmaceutical applications. As compared to the baicalin, the baicalin magnesium has a greatly increased solubility, faster adsorption rate and higher oral bioavailability. The baicalin magnesium compound may also be easily formulated as a water-soluble injection or a powder injection.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: February 5, 2019
    Assignee: CHENGDE MEDCIAL UNIVERSITY
    Inventors: Cuizhe Liu, Zhixuan Wang, Ceyu Miao, Liyan Liu, Hefei Xue, Xigang Liu, Wenshan Du, Yixin Liu, Lin Zhang, Xiaoxia Mao, Jinjun Liu, Guiqin Zhao
  • Patent number: 10155003
    Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: December 18, 2018
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna
  • Patent number: 10149877
    Abstract: The present invention relates to combinations of an agent that stimulates cell proliferation and an anti-inflammatory/analgesic, which are useful in the treatment of peripheral ulcers of various origins, such as radiation dermatitis, diabetic ulcers, ulcers caused by venous stasis of the limbs, bedsores, and the associated skin infections, proctitis, vulvovaginitis and haemorrhoids with vascular lesions. These combinations can be presented as formulations for topical use.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: December 11, 2018
    Assignee: INDENA S.P.A.
    Inventor: Ezio Bombardelli
  • Patent number: 10137136
    Abstract: In one aspect, the invention relates to methods for treating muscle atrophy by providing to an animal in need thereof an effective amount of a compound. The compound can modulate the expression levels of multiple mRNA of a muscle atrophy signature. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: November 27, 2018
    Assignees: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Christopher M. Adams, Steven D. Kunkel, Michael Welsh
  • Patent number: 10131727
    Abstract: The present invention relates to a process for the development of a highly efficient solid state matrix by the activation of acrylate based polymer resin having specialized functional groups with 1,1-Carboxyl diimidazole for immobilizing biologically active macromeloecules such as oxidases, in particular plant oxidases and the most preferred being tea polyphenol oxidase through indirect covalent bonding/cross linking on such activated polymer resin support, are thermally stable, gives very high number of turnovers in vitro (“n” times) with tea substrate forming exclusive product Theaflavins without any loss of biological activity and leaving the product remaining in vitro with adherence to matrix rendering the matrix safe towards product poisoning and subsequent partial or complete loss of biological activity of the matrix bound enzyme system and thus well adapted to and well suited biorectors based on such systems.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: November 20, 2018
    Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Harsh Pratap Singh, Kapil Sharma
  • Patent number: 10123992
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 13, 2018
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 10111854
    Abstract: The present invention relates to novel series of amine-containing flavonoids and compositions containing the compounds, as well as the synthesis and the use of the same. The invention also relates to methods of treatment and prevention of diseases, in particular, parasitic infections including Leishmaniasis, comprising administration of the compounds.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: October 30, 2018
    Assignee: The Hong Kong Polytechnic University
    Inventors: Larry Ming-Cheung Chow, Tak Hang William Chan, Kin-Fai Chan, Iris Lai King Wong, Wing-Yiu Kan
  • Patent number: 10098838
    Abstract: The invention relates to water-soluble granules for preparing a drinkable solution, in particular for preventing or treating symptoms associated with mild to moderate chronic venous insufficiency of the lower extremities, containing at least 20 percent by weight of a concentrated extract of red wine leaves, and to a ready-to-use packaging unit comprising one or more portion sachets which contain the granules according to the invention.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: October 16, 2018
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Sandra Sauerland, Sonja Heigenhauser, Uwe Scheuring, Oliver Timm
  • Patent number: RE47741
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R11 and R12 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: November 26, 2019
    Assignee: Achaogen, Inc.
    Inventors: Paola Dozzo, Adam Aaron Goldblum, James Bradley Aggen, Martin Sheringham Linsell